1Tono S,Shioi A,Lkari Y,et al.Vascular calcification in chronic kidney disease.J Bone Miner Metab,2006,24(2):176-181
2Moe SM,Chen NX.Pathophysiology of vascular calcification in chronic kidney disease.Circulation Research,2004,95:560
3Tsuda E,Coto M,Mochizuki S,et al.Isolation of a novel cytokine form human fibroblasts that specifically inhibits osteoclastogenesia.Bioche Biophys Res Commun,1997,234(1):137-142
4Sophie R,Philippe O.Bone loss:Factors that regulate osteoclast differentiation-an update.Arthritis Res,2000,2(6):451-456
5Kazama,Junichiro.Osteoprotegerin and bone mineral metabolism in renal failure.Curr Opin Nephrol Hypertens,2004,13 (4):411-415
6Hsu H,Lacey DL,Dunstan CR,et al.Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand.Proc Natl Acad Sci USA,1999,30,96(7):3540-3645
7Yasuda H,Shima N,Nakagawa N,et al.Osteoclast differentiation factor is a ligand for osteoprotegrin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL.Proc Natl Acad Sci USA,1998,31,95(7):3597-3602
9Jonathan Lam,Christopher A.Nelson,F.Patrick Ross,et al.Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity.J Clin Invest.2001,108(7):971-979
10Gori F,Hofbauer LC,Dunstan CR,et al.The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated.[J] Endocrinology,2000,141(12):4768-4776
